Floatz logo

Niraparib

ATM Gene Mutation

University of California, San FranciscoSmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the ATM Gene Mutation cohort.

Asset / SponsorPhaseRating
Carboplatin
University of Washington
Phase 2CCC
Rucaparib
University of Washington
Phase 2CCC
Olaparib
Beth Israel Deaconess Medical Center
Phase 2CCC
Talzenna
M.D. Anderson Cancer Center
Phase 2CCC
TAMOXIFEN
European Institute of Oncology
Phase 2CCC

View all 9 →

Same molecule, other indications

Niraparib is also rated in:

breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
ovarian neoplasmDormant
BB
Indicative ·
66 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →